NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.92 -0.08 (-0.10%) GOLD FUTURES
2,317.30 +6.30 (+0.27%) DOW
38,189.82 +286.53 (+0.76%) Bitcoin GBP
47,366.87 +1,234.60 (+2.68%)
Kirin Holdings Company, Limited (2503.T)
| Previous close | 2,300.00 |
| Open | 2,298.50 |
| Bid | 2,284.00 x 0 |
| Ask | 2,286.50 x 0 |
| Day's range | 2,276.50 - 2,298.50 |
| 52-week range | 1,983.00 - 2,305.00 |
| Volume | |
| Avg. volume | 3,134,311 |
| Market cap | 1.854T |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 16.45 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 71.00 (3.09%) |
| Ex-dividend date | 27 Jun 2024 |
| 1y target est | N/A |
- Business Wire
Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28!
TOKYO, November 27, 2023--Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday). This product is a collaboration between Kirin iMUSE, Japan’s first*1 immune care brand, and Kao Healthya, Japan’s first*1 body fat care beverage brand from Kao Corporation (TOKYO:4452), and will be sold at drugstores nationwide and through Kirin Kyowa Hakko Bio mail order.
- Business Wire
Japan’s First Discovery*1 on Visceral Fat and Immune Activity in Joint Research by Kirin Holdings and Kao
TOKYO, November 24, 2023--Kirin Holdings Company, Limited (TOKYO:2503) and Kao Corporation (TOKYO:4452) will participate in the Wakayama Health Promotion Study, a cohort study*2 led by Wakayama Medical University and organized by the Health Promotion Research Center (HPRC), a non-profit organization. Kao and Kirin Holdings conducted a joint study from November 2022 to investigate the relationship between visceral fat and the plasmacytoid dendritic cells (pDC*3) activity*4, which are the command
- Business Wire
Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19
TOKYO, May 11, 2023--Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19
